Neuroscience and Behavioral Physiology

, Volume 47, Issue 8, pp 904–907 | Cite as

Cognitive Impairments in Stroke: Potential for Medication-Based Correction

  • G. N. Bel’skaya
  • S. E. Chuprina
  • A. A. Vorob’ev
  • E. N. Gorozha
  • T. L. Butorakina
  • M. A. Sokolov
  • I. A. Izmailov
Article
  • 9 Downloads

Objective. To assess the efficacy and safety of Cellex for the correction of cognitive disorders in the acute period of ischemic stroke (IS). Materials and methods. The study included 246 patients in the acute period of IS. Patients were divided by random selection into two groups given Cellex or placebo for 10 days on the background of standard basal treatment. Patients were assessed dynamically in terms of neuropsychological status. Results and conclusions. This study showed that in patients with IS, mild and moderate cognitive impairments underwent faster and more marked regression when Cellex was prescribed (p < 0.05).

Keywords

ischemic stroke cognitive disorders neuroprotection treatment Cellex 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. V. Putilina, “Citicholine in the correction of vascular cognitive impairments in the prophylaxis of post-stroke vascular dementia,” Lech. Vrach, 11, 66–69 (2011), http://www.lvrach.ru/2011/11/15435306, acc. Aug. 28, 2015.
  2. 2.
    G. M. Savva and B. C. Stephan, Alzheimer’s Society Vascular Dementia Systematic Review Group, “Epidemiological studies of the effect of stroke on incident dementia: a systematic review,” Stroke, 4, 41–46 (2010), doi:  https://doi.org/10.1161/strokeaha.109.559880.CrossRefGoogle Scholar
  3. 3.
    K. Palmer, H.-X. Wang, L. Backman, et al., “Differential evolution of cognitive impairment in nondemented older persons,” Am. J. Psychiatry, 159, 436–442 (2002), doi:  https://doi.org/10.1176/appi.ajp.159.3.436.CrossRefPubMedGoogle Scholar
  4. 4.
    I. S. Preobrazhenskaya, “Post-stroke cognitive disorders: causes, clinical features, treatment,” Farmateka, 9, 49–53 (2013), http://www.bionika-media.ru/files/uploads/pharmateca/PDF/262/49-53.pdf, acc. Aug. 28, 2015.
  5. 5.
    M. A. Cherdak and V. A. Parfenov, “Cognitive disorders in patients with ischemic stroke: a review,” Nevrol. Zh., 16, No. 6, 37–44 (2011), http://www.medlit.ru/j/nev/nj110637.htm, acc. Aug. 28, 2015.
  6. 6.
    C. S. Ivan, S. Seshadri, A. Beiser, et al., “Dementia after stroke: the Framingham Study,” Stroke, 35, 1264–1268 (2004), doi:  https://doi.org/10.1161/01.str.0000127810.92616.78.CrossRefPubMedGoogle Scholar
  7. 7.
    N. V. Shakhparonova and A. S. Kadykov, “Post-stroke cognitive impairments. Potential for drug-based correction using Citicholine (ceraxon),” Atmosf. Nerv. Bol., 2, 16–19 (2011), http://www.atmosphere-ph.ru/modules/Magazines/articles/nervo/an_2_2011_16.pdf, acc. Aug. 28, 2015.
  8. 8.
    V. V. Zakharov and N. V. Vakhnina, “Cognitive impairments in cerebrovascular diseases,” Nevrol. Psikhiatr., No. 1, 36–43 (2014), http://noopept.ru/themes/m/docs/6.pdf, acc. Aug. 28, 2015.
  9. 9.
    N. V. Vakhnina, “Vascular cognitive impairments,” Nevrol. Neiropsikhiatr. Psikhosom., No. 1, 74–79 (2014), doi:  10.14412/2074-2711-2014-1-74-79.
  10. 10.
    S. T. Pendlebury and P. M. Rothwell, “Prevalence, incidence and factors associated with prestroke and post-stroke dementia: a systematic review and metaanalysis,” Lancet Neurol., 8, No. 11, 1006–1018 (2009), doi:  https://doi.org/10.1016/s1474-4422(09)70236-4.CrossRefPubMedGoogle Scholar
  11. 11.
    U. Sundar and S. Adwani, “Post-stroke cognitive impairment after 3 months,” Ann. Indian Acad. Neurol., 13, No. 1, 42–46 (2010), doi:  https://doi.org/10.4103/0972-2327.61276.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Y. Dong, V. K. Sharma, B. P. Chan, et al., “The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for detection of vascular cognitive impairment after acute stroke,” J. Neurosci., 299, No. 1–2, 15–18 (2010), doi:  https://doi.org/10.1016/j.jns.2010.08.051.Google Scholar
  13. 13.
    N. V. Pizova, “Characteristics of cognitive disorders after stroke: diagnosis and therapeutic approaches,” Nevrol. Neiropsikhiatr. Psikhosom., No. 2, 56–61 (2013), nnp.ima-press.net/index.php/nnp/article/download/211/214, acc. Aug. 28, 2015.
  14. 14.
    N. G. Kataeva, N. A. Kornetov, E. V. Karavaeva, et al., “Cognitive impairments after stroke,” Nevrol. Neiropsikhiatr. Psikhosom., No. 1, 37–41 (2010), doi:  10.14412/2074-2711-2010-68.
  15. 15.
    J. Alvarez-Sabin and G. C. Roman, “Citicoline in vascular cognitive impairment and vascular dementia after stroke,” Stroke, 42, No. 1, 40–43 (2010), doi:  https://doi.org/10.1161/strokeaha.110.606509.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • G. N. Bel’skaya
    • 1
  • S. E. Chuprina
    • 2
  • A. A. Vorob’ev
    • 2
  • E. N. Gorozha
    • 2
  • T. L. Butorakina
    • 3
  • M. A. Sokolov
    • 4
  • I. A. Izmailov
    • 4
  1. 1.South Urals State Medical UniversityChelyabinskRussia
  2. 2.Voronezh Regional Clinical Hospital No. 1VoronezhRussia
  3. 3.Hospital No. 33, Russian Federal Medical Biological AgencyNovovoronezhRussia
  4. 4.Farm-SintezMoscowRussia

Personalised recommendations